2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5121 Gilteritinib, venetoclax, and azacitidine versus gilteritinib plus intensive chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: A real-world analysis

Feifei Tang, MD, PhD, Xinyi Qi2, Xiaosu Zhao3, Qian Jiang Jr, MD4, Hao Jiang5, Lanping Xu, MD6, Xiaohui Zhang, MD, PhD7
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China

Background

Relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) typically carries a poor prognosis. Although gilteritinib improves survival compared with salvage chemotherapy, responses are often neither deep nor durable, prompting its combination with venetoclax and azacitidine (GVA) or intensive chemotherapy (GIC). However, real-world data directly comparing the clinical outcomes and safety profiles of these two combination regimens in R/R cohorts remain scarce.

Aim

We aimed to compare the clinical characteristics, treatment efficacy, safety, and prognosis of GVA and GIC in patients with R/R FLT3-mutated AML in a real-world cohort in China.

Methods

We analyzed the baseline characteristics and clinical outcomes of 91 patients with R/R FLT3-mutated AML, including 71 patients treated with GVA and 20 treated with GIC. We evaluated and compared treatment response, measurable residual disease (MRD) response, hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) outcomes, early mortality, overall survival (OS), and disease-free survival (DFS) between the two cohorts.

Results

A total of 91 patients with relapsed/refractory FLT3-mutated AML were included, of whom 71 received GVA and 20 received GIC. GVA had similar mCRc (CR+CRi+MLFS), 1-year OS, and 1-year DFS compared to GIC (mCRc: 70.4% vs. 75.0%, P=0.790; OS: 70.4% vs. 70.0%, P=0.276; DFS: 55.5% vs. 76.5%, P=0.267). Among 84 patients with evaluable FLT3-MRD data, the rate of FLT3-MRD negativity after cycle 2 was similar between the GVA and GIC groups (42.4% vs. 55.6%, P=0.450). Among 45 patients with evaluable hematologic recovery data, there were no significant differences between the GVA and GIC groups in the median time to ANC recovery (41.0 vs. 41.5 days, P=0.832) and platelet recovery (24.0 vs. 35.0 days, P=0.345). In the GVA group, GATA2 and IDH1 mutations were independently associated with inferior OS (GATA2: HR=6.22, 95% CI 1.41–27.55, P=0.016; IDH1: HR=3.77, 95% CI 1.06–13.37, P=0.040). Patients with a non-FLT3 mutation burden ≥3 had inferior 1-year OS (67.9% vs. 72.1%, P=0.031) and DFS (42.0% vs. 64.9%, P=0.027) in the GVA group. The VEN-adverse genotype (RAS-pathway/TP53 mutations) predicted inferior 1-year DFS (40.0% vs. 62.8%, P=0.039), while NPM1 plus RAS-pathway co-mutations predicted inferior 1-year OS (50.0% vs. 72.3%, P=0.048) in this cohort. In the GIC group, bone marrow blasts ≥30% (42.9% vs. 84.6%, P=0.037), WBC ≥15 × 10?/L (33.3% vs. 85.7%, P=0.026), and MLL-PTD (0.0% vs. 73.7%, P=0.039) predicted inferior 1-year OS, whereas tumor-suppressor pathway alterations (TP53, WT1, or PHF6) and WT1 mutations predicted inferior 1-year DFS (50.0% vs. 84.6% and 33.3% vs. 85.7%, respectively; P=0.021). In multivariate analysis, GATA2 and IDH1 mutations predicted inferior OS in the GVA group (GATA2: HR 6.22, P=0.016; IDH1: HR 3.77, P=0.040), whereas allo-HSCT predicted improved OS and DFS (OS: HR 0.17, P<0.001; DFS: HR 0.28, P<0.001).

Conclusion

GVA and GIC achieved comparable mCRc and survival outcomes in patients with R/R FLT3-mutated AML. However, distinct baseline clinical and mutational profiles dictated the differential efficacy of each regimen. Specifically, GIC may be more suitable for patients harboring the venetoclax-adverse genotype or a non-FLT3 mutation burden ≥3, whereas patients with tumor-suppressor pathway alterations may derive a greater DFS benefit from GVA.
Xinyi Qi: No relevant conflicts of interest to declare.